![Christine Siu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Christine Siu
Directeur/Membre du Conseil chez
MONTE ROSA THERAPEUTICS, INC.
Fortune : - $ au 31/05/2026
Profil
Mme Christine E. Siu est directrice de l'exploitation chez BridgeBio Pharma, Inc. Elle est membre du conseil d'administration de Vividion Therapeutics, Inc. et de Monte Rosa Therapeutics, Inc. Auparavant, Mme Siu a occupé les postes de directrice financière et comptable chez Eidos Therapeutics, Inc. et de directrice commerciale chez The Bluefield Project to Cure Frontotemporal Dementia, de directrice principale des opérations et du développement commercial chez Global Blood Therapeutics, Inc. et de directrice principale chez Third Rock Ventures LLC, de vice-présidente chez Thomas, McNerney & Partners LLC, d'analyste chez Bear, Stearns & Co, Inc. et de gestionnaire de portefeuille chez Warburg Pincus LLC. Elle a également été membre du conseil d'administration de NeuroTherapeutics Pharma, Inc. Elle a obtenu son diplôme de premier cycle à l'université du Michigan et un MBA à la Harvard Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 11/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Christine Siu
| Sociétés | Poste | Début |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/12/2020 |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Directeur/Membre du Conseil | 04/05/2021 |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Directeur/Membre du Conseil | 10/06/2021 |
Bright Peak Therapeutics, Inc.
 Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Christine Siu
| Sociétés | Poste | Fin |
|---|---|---|
| BRIDGEBIO PHARMA, INC. | Directeur des opérations | 23/07/2024 |
| EIDOS THERAPEUTICS, INC. | Directeur Financier/CFO | 31/12/2019 |
The Bluefield Project to Cure Frontotemporal Dementia
 The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | Corporate Officer/Principal | 01/01/2017 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Directeur des opérations | 01/01/2014 |
Thomas, McNerney & Partners LLC
 Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Analyste en capital-investissement | 31/12/2010 |
Formation de Christine Siu
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
16
Relations au 1er degré
15
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 15 |
|---|---|
Bear, Stearns & Co., Inc.
 Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Provides investment banking, securities trading and brokerage Services | Finance |
Warburg Pincus LLC
 Warburg Pincus LLC Investment ManagersFinance Warburg Pincus invests in companies located across the globe. The firm focuses on a broad range of sectors and industries. It provides financing for buyout transactions. | Finance |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thomas, McNerney & Partners LLC
Thomas, McNerney & Partners LLC Investment ManagersFinance TMT invests in companies located in the United States. The firm targets companies operating in the fields of life sciences and medical technology. It participates in restructuring transactions including spin-outs, roll ups and recapitalizations with an investment size of USD 5 - 40 million. | Finance |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
NeuroTherapeutics Pharma, Inc.
 NeuroTherapeutics Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical and therapeutic drugs for central nervous system disorders | Health Technology |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Bluefield Project to Cure Frontotemporal Dementia
The Bluefield Project to Cure Frontotemporal Dementia The Bluefield Project to Cure Frontotemporal Dementia is a non-profit organization focused on accelerating the development of treatments and finding a cure for frontotemporal dementia (FTD), a fatal early-onset brain disease primarily affecting people under 60. The private company is based in San Francisco, CA. The organization targets FTD caused by mutations in the progranulin gene (GRN), funding basic, translational, and clinical research through a consortium of academic institutions and fostering collaboration between scientists and clinicians. Key therapeutic priorities include increasing progranulin levels, reducing neuroinflammation, and improving lysosomal function and protein homeostasis. Bluefield also supports biomarker studies and patient registries to aid research and clinical trial enrollment. The company was founded by Richards Donohoe Robin. | |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology research company which develops precision therapeutics for cancers and immune disorders | Health Technology |
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
BridgeBio Pharma, Inc.
 BridgeBio Pharma, Inc. BiotechnologyHealth Technology Develops medicines for genetic diseases to patients | Health Technology |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Bright Peak Therapeutics, Inc.
Bright Peak Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for the treatment of cancer and autoimmune diseases | Health Technology |
